ProCE Banner Activity

CE

Leveraging IV Robotics and IV Workflow to Optimize Sterile Compounding Practices to Improve Safety

Video

This webinar will review the rationale for the use of IV robotics, as well as the challenges with adoping this technology, including a discussion of preparing for and implementing IV robotics, the need for obtaining 'buy-in' from leadership and pharmacy staff to purchase and implement IV robotics, and the role this technology has played in improving safety.  The speaker will also discuss what processess need to change prior to implementation, leassons learned from both the implementation and use of IV robotics, as well as case examples of errors that occrred prior to IV robotics use and the safety improvement from its use.  The program will end with a question-and-answer period. 

Pharmacy Technicians: maximum of 1.00 contact hours

Pharmacists: maximum of 1.00 contact hours

Released: April 23, 2024

Expiration: April 23, 2026

Share

Faculty

Arpit Mehta

Arpit Mehta, PharmD, MPH, MHA, CPEL, FASHP

Director of Pharmacy

AHN Allegheny General Hospital

Pittsburgh, PA

Acknowledgement

This activity is supported by an independent educational grant from Omnicell

Provider Statement

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and the Institute for Safe Medication Practices (ISMP)

Target Audience

Medication Safety and Patient Safety Officers, Risk Management and Quality Managers, Medication Safety Committees, Nurses, Pharmacists, Pharmacy Technicians, and Physicians

Learning Objectives

  • Describe the role of robotics and workflow in the advancement of safety during sterile compounding operations

  • Review the necessary changes in workflows and processes required prior to and after the implementation of IV robotics and workflow

  • Describe the challenges associated with obtaining buy-in from leadership and pharmacy staff for the implementation of IV robotic technologies including steps taken to address perceived barriers.

  • Review the benefits of leveraging a service model vs. traditional model of purchasing IV robotics

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Arpit Mehta, PharmD, MPH, MHA, CPEL, faculty for this activity, has no relevant financial relationships.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Institute for Safe Medication Practices.  PACE is jointly Accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-24-095-H05-P/T)
Type of Activity: Knowledge

Additional Information

Instructions for Credit

  1. There are no fees for participating in and receiving CE credit for this activity.
  2. During the period April 22, 2024 through April 22, 2026, participants must read the educational objectives and faculty disclosures and study the educational activity.
  3. If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
  4. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
  5. Pharmacists/Technicians: Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Estimated time to complete activity: 1.0 hour